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1075MP-165 Clopfdogrel Pretreatment Prior to Percutaneous 
Coronary Intervention Attenuates Periprocedural Rise 
of C-Reactive Protein 
9:24 a.m. 
Deeoak P. Vivekananthaq Deepak L. Bhatt, Derek P. Chew, Albert W. Ghan, David J. 
Molitemo, Stephen G. Ellis, Eric J. Topol, The Cleveland Clinic Foundation, Cleveland, 
OH, Flinders Medical Centre, South Australia, Australia 
Introduction: Pretreatment with clopidogrel prior to percutaneous coronary intervention 
(PCI) has been associated with reduced rates of death and myocardial infarction (Ml). 
Clopidogrel pretreatment has also been found to be most efficwous in patients with high 
baseline levels of C-reactive protein (CRP), suggesting an antI-inflammatory effect. How- 
ever, it is unknown whether clopidogrel pretreatment attenuates the rise in CRP after 
PCI. 
Methods: We followed 635 consecutive patients in our PCI registry from 2000.2002 who 
had both preprocedural and postprocedural (within 24 hours) levels of ultrasensitive CRP 
drawn. Clopidogrel pretreatment was left to the discretion of the treating physician. We 
determmed the association behveen clopidogrel pretreatment and change in CRP after 
PCI. 
Results: Besides aspirin, a total of 262 patients were pretreated with clopidogrel and 553 
patients received no clopidogrel pretreatment. Patients pretreated with clopidogrel were 
more likely to be diabetic, to be using statins, and to have an acute coronary syndrome 
on presentation. The median baseline levels of CRP were similar between pretreatment 
patients and patients who received no pretreatment, 0.39 mgldl and 0.36 mgldl (P=O.69), 
respectively. However, the mean rise in CRP after PC1 was significantly attenuated with 
clopidogrel pretreatment compared to the nb pretreatment group (O.l5mg/dl vs. 0.43 mg/ 
dl, P=O.O26). After controlling for clinical and angiographic factors with linear regression 
analysis, clopidogrel pretreatment significantly attenuated the rise in CRP 24 hours after 
PCI (regression coefficient: -0.30, 95% Cl [-0.60 ,-O.Ol], P=O.O4). 
Conclusion: Clopidogrel pretreatment prior to PCI is associated with a significant atten- 
uation in periprocedural rise of CRP. This study adds to the growing evidence of the anti- 
inflammatory effects of clopidogre’. Further study is needed to determine whether the 
attenuation in CRP rise after PCI is the primary mechanism for the reduction in subse- 
quent death and Ml associated with clopidogrel. 
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1075MP-166 Cardioprotective Effect of Chronic Treatment With 
Statins Prior to Percutaneous Coronary Intervention 
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Background: The presence of elevated level of Troponin I, an highly sensitive and spe- 
cific marker of cardiac damage, has a negative prognostic value after percutaneous COT- 
onary angioplasty (PCI). Statins seem to have many different actions beside the 
cholesterol levels lowering one, i.e. vasodilatation, antioxidant and anti-proliferative effect 
and, probably, they may exert a protective action on endothelial function. Aim of this 
study is to verify whether a chronic treatment with Statins could reduce cardiac damage 
after PCI. 
Methods: 164 patient (pts), who underwent PCI because of the presence of angina1 
symptoms or evidence of inducible myocardial ischemia, were divided into two groups 
according to the presence (Gl) or absence (G2) of statins in their therapy before PCI (for 
at least 3 months prior to the procedure): Gl included 66 pts and G2 96 pts Troponin I 
levels were evaluated 6-12-24 hours after the procedure. Troponin I was defined positive 
if its blood levels were greater than 0.1 ng/dl. 
Results: Unstable angina was present in 17% of Gl and 23% of G2 pts. Multivessel dis- 
ease was present in 56% of Gl and 57% of G2 pts. One-vessel-PC1 was performed in 
90% of Gl and 64% of G2 pts. Troponin values remained normal in 41% of Gl pts and 
22% of G2. Troponin I >= 1 .O ng/dl was present in 4.5% of Gl and 21% of G2 (p=O.OOl). 
Multivariate analysis confirmed the relationship between statins therapy and the varia- 
tions of Troponin levels after PCI (p=O.Ol) 
Conclusions: pts not treated with statins before PCI showed significantly more frequent 
abnormal Troponin I values after the procedure. These results suggest a possible protec- 
tive role of statlns against myocardial damage during PCI. 
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1075MP-167 Restenosis Is Not Increased in Mild or Moderate 
Chronic Kidney Disease: Results From the PRESTO 
Trfal 
Patricia J. M. Best, Peter B. Berger. Jeffrey R. Grannett, Barry R. Davis, James T. 
Willerson, David R. Holmes, Jr., Mayo Clinic and Foundation, Rochester, MN 
Background: Patients with chronic kidney disease (CKD) have an increased mortality 
after percutaneous coronary intervention (PCI). Even mild CKD doubles one-year mortal- 
ity. Restenosis may contribute to the increased late mortality in these patients. In the 
CKD population, restenosis is significantly increased with balloon angioplasty alone. No 
studies have prospectively determined if restenosis is increased in CKD after PCI in the 
current stenting era. 
Methods: We analysed 11,167 patients from the Prevention of REStenosis with Tranilast 
and its Outcomes (PRESTO) trial and categorized them by estimated creatinine clear- 
ance (<60 mlimin [n=l,749], 60-69 ml/min (n=4,054], >69 ml/min [n=5,364]) using the 
Cockroft-Gault formula. Chl-squared tests were used to investigate the association 
between the creatinine clearance group and death or myocardlal infarction or target ves- 
sel revascularization and a generalized estimating equation model was used to deter- 
mine the interaction with restenosis. 
Results: Pattents in the lowest creatinine clearance group were older, had a greater pro- 
portlon of women, and had more diabetes. At 30 days, there was no difference in 
adverse events between those in the lowest, mlddle, and highest creatinine clearance 
groups in terms of myocardial infarction (1% vs. O%, vs. O%, p=O.33), death (0%. vs. O%, 
vs. O%, p=O.O6), or target vessel revascularization (l%, vs. l%, vs. l%, ~~0.28) respec- 
tively. At 9 months, mortality was higher in the lowest creatinine clearance group (2% vs. 
1% vs. l%, p <O.OOl), but myocardial infarction and target vessel revascularization were 
not different. In patients undergoing protocol follow-up angiography (n=2,556), restenosis 
was not increased with CKD (32% vs. 32% vs. 37%. p=O.l3). 
Conclusion: Mortality at 9 months is mildly increased in patients with mild or moderate 
CKD after PCI. Restenosis is not increased in CKD and does not account for this 
increased mortality. 
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Background: lntracoronary Radiation Therapy (IRT) reduces the recurrence of in-stent 
restenosis (ISR). The use of Ilb/llla inhibitors in conventional PCI reported to reduce CK 
release and cardiac events. This study examined the impact llblllla inhibitors as adjunct 
therapy to IRT for patients with ISR. 
Methods: INTEGRILIN WRIST was designed as a randomized 1:l open label study for 
300 patients with diffuse ISR in native coronaries and vein grafts with lesions ~60 mm, 
who underwent PCI (re-stenting in 43%) followed by IRT utilizing k-192 emitter dose of 
15 Gy at 2 mm. In the study 150 patients assigned to Eftibatide (Integrilin) with double 
bolus of 160 mcglkg and 2.0 mcglkg-min infusion xl6 hours + heparln 60 U/kg bolus 
(ACT 200-300 set) and 150 patients to heparin only. Patients were discharged with clopi- 
dogrel 75 mg/QD for 6 months. The primary objectives of this study were clinical com- 
posite endpoints, CKMB, MI, death and target lesion revascularization. 
Results: Baseline clmical, angiographic, and procedural characteristics were similar fo[ 
patients with and without Eftibatide. The use of Eftibatide was not associated with an 
increase in bleeding. Clinical composite endpoints at 30 days were similar between the 
patients treated with and without Eftibatide (Table). 
Conclusion: The use of Eftibatide as adjunct therapy for patients with ISR that are 
treated with IRT does not impact the clinical outcome at 30 days. The 9 month clinical 
and angiographic results will be ready at presentation. 
In hospital and 30 days follow-up 
Eftibatide Control P 
TVR MACE 1.4 2.6 0.62 
Q-MI 1.4 2.1 0.62 
non Q-MI 19.9 16.4 0.76 
CK-MB>3 15.4 19.5 0.37 
Vascular Complications 4.6 1.4 0.10 
Bleeding 7.5 4.3 0.24 
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1075MP-169 Oral Sirolimus to Prevent Restenosis After Stenting De 
Novo Coronary Lesions 
Costantino R. Costantini, Daniel Zanuttini. Sergio Tarbine, Rubens Dalwich, Jose L. 
Lazarte, Costantino 0. Costantini, Mario Maranhao, Manuel Andrade, Maria R. Oliveira, 
Luis Sabattini, Gilson Yared, Marco Bubna, Marco Medeiro. Laura Rubbini, Marcel0 
Freitas, Clinica Cardiologyca C Costantini, Curitiba, Brazil 
Background: Sirolimus drug-eluted stem (DES) suppress intimal hyperplasia in pts with 
denovo (DN) coronary lesions. We conducted a prospectwe clinical study to assess the 
safety and efficacy of oral Sirolimus for prevention of restenosis after DN lesions Stem 
implantation 
Methods: From 1 l/2001 to 6/2002, 22 DN coronary lesions underwent stent PCI in 20 
pts. Treatment with oral sirolimus was started with a loading dose of 6mg before PCI fol- 
lowed by Pmglday for 14 days. Before PCI. at 10 days, 1 and 6 months pts were clinically 
assessed and serum electrolytes, lipid profile, renal panel, and complete blood count 
were measured. Anglographic and IVUS volumetric analysis were performed at baseline 
and at 4 months follow-up. 
Results: The mean age was 6427 years, 75% were male and 20% had Dhi. Baseline 
mean reference diameter was 3.16 * 0.35mm, MLD was 1.0&0.24 and DS 65%. 22 BX 
Velocity (Cordis) stents were implanted guided by IVUS with a mean pressure of 
17.2r2.latm. Angiographic success was 100% with a final MLD of 3.lkO.6 and DS% of 
